← FDA Drug Approvals (Drugs@FDA)

LINAGLIPTIN

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: INVAGEN PHARMS · Approved 2024-09-03

Drug application

FDA Application #

ANDA208423

Application type

Abbreviated New Drug Application (Generic)

Brand name

LINAGLIPTIN

Generic name

Linagliptin

Active ingredients

LINAGLIPTIN

Dosage form

TABLET

Route

ORAL

Marketing status

Prescription

Sponsor

INVAGEN PHARMS

First approval

2024-09-03

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown